|Bid||132.00 x 800|
|Ask||134.75 x 1000|
|Day's Range||133.38 - 140.03|
|52 Week Range||46.07 - 176.50|
|Beta (3Y Monthly)||1.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||196.52|
Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $1.72 billion.
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, will report third quarter 2018 financial results after the Nasdaq Global Market closes on Wednesday, October 24, 2018. Subsequently, at 4:30 p.m. Eastern Time, the Company will host a conference call to discuss its third quarter 2018 financial results and to provide a corporate update. The conference call may be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for international callers.
“Kendall Square has become, in a sense, the center of the universe for biotech because of the deep relationship between biotech companies and MIT and Harvard,” CEO Doug Ingram said.
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics Inc. plans to open the first phase of its Gene Therapy Center of Excellence in Columbus by spring and expand throughout 2019 – eventually 85,000 square feet and 100 high-paying jobs. The CEO thinks Columbus could be for gene therapy what Cambridge is for biotech.
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
-- Expands Sarepta’s portfolio to as many as 14 gene therapy programs -- -- Mucopolysaccharidosis type IIIA (MPS IIIA), also called Sanfilippo syndrome type A, is a rare,.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Sarepta Therapeutics Inc (NASDAQ:SRPT), with a market capitalization of US$8.1b, rarely draw their attention from the investing Read More...
Sarepta Therapeutics (SRPT) incurred net interest expenses of $5.22 million in the second quarter, compared with net interest income of $184,000 in the second quarter of 2017. Its net loss is expected to be $233.25 million in fiscal 2018 and $93.99 million in fiscal 2019.
Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company that develops unique RNA-targeted therapeutics, gene therapy, and other approaches for rare neuromuscular diseases. Sarepta’s first product on the market, Exondys 51, was approved in the United States in September 2016 for treating Duchenne muscular dystrophy (or DMD) for patients with a confirmed mutation of the DMD gene. To drive product sales, Sarepta Therapeutics has begun a market access program for Exondys 51 in countries where it hasn’t been approved in Europe, North America, South America, and Asia.
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
Sarepta has seen its share price decline in the wake of data from a small study of its gene therapy drug for Duchenne muscular dystrophy. But the Cambridge biotech is moving forward with its clinical trial work and expansion plans.
The easy trade this morning would have been a big emotional gap down open but every algorithm out there was ready to buy that setup so they ended up buying before the open instead. The big bounce in futures occurred in the two hours before the open and undercut the easy 'buy the dip' setup.
In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy. The FDA grants this designation to support the development of therapies for rare diseases. This designation provides benefits such as seven years of market exclusivity after approval, tax credits for certain clinical trials, and exemption of FDA application fees.
CAMBRIDGE, Mass., Oct. 08, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision.
Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding SRPT is favorable, with net inflows of $7.09 billion.
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today it has signed an agreement with Nationwide Children’s Hospital (Nationwide Children’s) giving Sarepta the exclusive option to a Nationwide Children’s gene therapy candidate, neurotrophin 3 (NT-3), to treat Charcot-Marie-Tooth (CMT) neuropathies, including CMT type 1A. CMT is a group of hereditary, degenerative nerve diseases that can affect motor skills, resulting in muscle weakness, and limiting patients’ ability to walk or use their hands.
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Major U.S. markets closed up on Wednesday, with the Dow Jones hitting a record high for the 15th time this year on upbeat economic data. However, market gains ...